Jazz enrolls first patient in JZP-110’s phase 2 trial for excessive sleepiness in PD patients
Jazz Pharmaceuticals plc \announced that the first patient has been enrolled in a Phase 2 clinical study evaluating JZP-110, a selective dopamine and norepinephrine reuptake inhibitor,…
Read More...
Read More...